Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

A closer look at the potential of Takeda’s Takhzyro in pediatric hereditary angioedema study

By Brian Buntz | July 15, 2022

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50Takeda (NYSE:TAK) recently announced that in the open-label Phase 3 SPRING study, children aged 2 to 12 had 94.8% fewer hereditary angioedema (HAE) attacks when receiving Takhzyro (lanadelumab-flyo) over 52 weeks compared to baseline

The primary objectives of the SPRING study was to evaluate the safety and pharmacokinetics of Takhzyro in HAE patients aged 2 to <12 years. The prevention of HAE attacks was a secondary outcome measure.

FDA first approved Takyzyro for hereditary angioedema in 2018 for patients 12 years and older with types I and II HAE. The drug won marketing authorization throughout the European Union that same year.

To learn more about the study, we reached out to Dr. Marcus Maurer, professor of dermatology and allergy at Charité – Universitätsmedizin Berlin, Germany and principal investigator of the SPRING study.

Drug Discovery & Development (DDD): The 94.8% reduction in HAE attacks for children aged 2 to <12 seems remarkable. Could you help put this figure in context and how it can reduce the unpredictable symptoms associated with HAE?

Dr. Marcus Maurer

Dr. Marcus Maurer

Maurer: Yes, we were very pleased with the data as we saw attacks among children reduce from 1.84 attacks per month to 0.08 attacks during treatment. Additionally, a majority (76.2%) of children were attack-free for the entirety of the treatment period, with an average of 99.5% attack-free days—promising results as we work to reduce the unpredictable and potentially fatal symptoms of HAE.

DDD: If Takhzyro wins regulatory approval for use in HAE patients younger than 6 years, how do you think the availability of the drug would affect the treatment of this demographic in particular?

Maurer: There currently are no long-term prophylactic treatments approved for HAE patients younger than 6 years old. Because of this, many children are experiencing unpredictable symptoms like debilitating swelling, including life-threatening laryngeal swelling as young as 3 years old. The potential approval of a long-term prophylactic treatment would provide pediatric patients and their caregivers the option to prevent HAE attacks rather than simply react to attacks as they happen.

DDD: The SPRING study results were in line with the favorable efficacy and safety profile of TAKHYZRO observed in earlier studies involving adults and adolescents. Could you provide a brief overview of its safety profile in younger children?

Maurer: The primary objective of the open-label, multicenter, Phase 3 SPRING study was to evaluate the safety and pharmacokinetics (PK) of Takhzyro in patients aged 2 to <12 years with HAE. Clinical outcomes were defined as prevention of HAE attacks and measured as a secondary objective. No deaths or serious treatment-emergent adverse events (TEAEs) were reported during the study, and no patients withdrew from the study due to TEAEs. The most commonly reported TEAE was injection site pain, and most TEAEs were mild or moderate in severity — all of which was in line with the safety results seen in the older populations.


Filed Under: Allergists, clinical trials, Drug Discovery, Immunology
Tagged With: HAE, hereditary angioedema, Takeda, Takhzyro
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Sai Life Sciences exec: GLP-1 boom has ‘exploded the peptide field’ as firm opens new center
Novartis in the Pharma 50
Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE